CTI BioPharma Corp. (CTIC) and Its Competitors Head to Head Comparison

CTI BioPharma Corp. (NASDAQ: CTIC) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare CTI BioPharma Corp. to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CTI BioPharma Corp. and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CTI BioPharma Corp. 0 0 1 0 3.00
CTI BioPharma Corp. Competitors 480 2263 6195 119 2.66

CTI BioPharma Corp. currently has a consensus price target of $7.50, suggesting a potential upside of 133.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.65%. Given CTI BioPharma Corp.’s stronger consensus rating and higher probable upside, equities analysts plainly believe CTI BioPharma Corp. is more favorable than its rivals.


This table compares CTI BioPharma Corp. and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CTI BioPharma Corp. -136.76% -418.99% -73.69%
CTI BioPharma Corp. Competitors -4,051.65% -118.57% -44.01%

Institutional & Insider Ownership

42.9% of CTI BioPharma Corp. shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 8.1% of CTI BioPharma Corp. shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

CTI BioPharma Corp. has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, CTI BioPharma Corp.’s rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.

Earnings & Valuation

This table compares CTI BioPharma Corp. and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
CTI BioPharma Corp. $36.55 million -$50.38 million -1.68
CTI BioPharma Corp. Competitors $207.79 million -$2.30 million 0.47

CTI BioPharma Corp.’s rivals have higher revenue and earnings than CTI BioPharma Corp.. CTI BioPharma Corp. is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


CTI BioPharma Corp. rivals beat CTI BioPharma Corp. on 8 of the 12 factors compared.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply